RE:RE:RE:RE:Pelareorep + Paclitaxel = Metastatic HR+/HER2– Breast CancerApril 23, 2024 - Novartis investors are anxiously awaiting another label expansion for Kisqali in early-stage HR-positive, HER2-negative breast cancer, for which the company filed an FDA application in December. [ Kisqali (Ribociclib) is used in combination with letrozole in patients with hormone receptor (HR)-positive, HER-2 negative advanced or metastatic breast cancer. It is also used together with fulvestrant to treat HR-positive, HER-2 negative advanced or metastatic breast cancer in postmenopausal women or in men. Ribociclib belongs to the group of medicines called antineoplastics. It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other unwanted effects will also occur. ]
https://www.fiercepharma.com/pharma/novartis-dials-2024-sales-outlook-preps-key-expansions-3-cancer-drugs